Millipore and JPT Peptide Technologies Enter into a Distribution Agreement for Peptide-Based Enzyme Profiling Tools

Billerica, Massachusetts and Berlin, Germany – September 28, 2006:
Millipore Corporation (NYSE: MIL) and JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of Berlin-based Jerini AG (FSE: JI4), today announced a distribution and marketing agreement. This relationship gives Millipore worldwide, non-exclusive distribution rights for JPT’s line of enzyme profiling products and services targeting enzymes such as kinases, phosphatases and proteases. This includes JPT’s line of Enzyme Substrate Sets and Microarrays containing thousands of peptides with annotated phosphorylation/cleavage sites to study enzymatic activities and substrate specificities. "JPT’s unique peptide-based products strongly complement our existing portfolio of cell signaling reagents and services,” states Rick Ryan, vice president of the Drug Discovery business unit for the Bioscience Division of Millipore Corporation. “This will give Millipore customers access to patented high-throughput peptide synthesis and screening platforms, which accelerates research in the field of signal transduction." Millipore offers a broad range of research products, including specialty reagents, kits, antibodies and molecular biology tools to a variety of research customers. It specializes in tools for kinase research and is a leading providers of drug discovery services to pharmaceutical companies targeting kinase biology-based drugs. The company also has ion-channel drug screening services to pharmaceutical companies. Ion channel screening is an important tool for detecting potentially toxic side effects in therapeutic compounds. "We applied our peptide synthesis and peptide array technologies to develop a series of tailor-made products and services to address the increasing demand in the field of kinase and protease research. We look forward to expanding the availability of these tools through Millipore’s worldwide, dedicated sales channels," comments Holger Wenschuh, managing director at JPT. Millipore’s Bioscience division delivers complete solutions and services for pharmaceutical, academic, life science, clinical and government research laboratories. With more than 50 years of experience, Millipore manufactures and markets several thousands of products that accelerate drug screening and improve sample preparation. For more information, please contact Millipore Tech Service at 1-800-MILLIPORE, 781-533-6000 or visit

About Millipore:

Millipore is a leading provider of products and services that improve productivity in biopharmaceutical manufacturing and in clinical, analytical and research laboratories. The Company is organized in two operating divisions. Its Bioprocess Division helps enables pharmaceutical and biotechnology companies to optimize their manufacturing productivity, ensure the quality of drugs, and scale up the production of difficult-to-manufacture biologics. Its Bioscience division helps to optimize laboratory productivity and workflows. Its products and enabling technologies that are used in the laboratory are essential for the research and development of biologically based life science therapeutics. Millipore has a deep understanding of its customers’ research and manufacturing process needs, and offers reliable and innovative tools, technologies and services. The Company is part of the S&P 500 index and employs approximately 5,800 employees in more than 47 offices worldwide. For additional information on Millipore Corporation, please visit its website at:

About JPT Peptide Technologies GmbH:

JPT Peptide Technologies GmbH is a leading provider of peptide-based research tools for applications that focus on vaccine development, peptide biomarker discovery and enzyme profiling. On the basis of its patented high-throughput synthesis and screening platform SPOT™, its peptide microarray technology PepStar™ and PepMix™ – a new approach for antigen-specific T-cell stimulation – JPT has developed a series of innovative products and services to facilitate the development of novel immunotherapies and immune-monitoring tools. JPT’s ability to produce highly complex peptide libraries and peptide arrays enable for the first time the discovery and profiling of B- and T-cell epitopes on proteome-wide levels as well as the development of tools to monitor the immune status of diverse patient populations suffering from infectious and autoimmune diseases, allergies and cancer. JPT is a wholly-owned subsidiary of Berlin-based Jerini AG and has an office in Springfield, VA, USA. For more information, please visit Millipore is a registered trademark of Millipore Corporation. SPOT, PepStar and PepMix are trademarks of JPT Peptide Technologies GmbH.


For further information please contact:

JPT Peptide Technologies GmbH
Dr. Holger Wenschuh
Managing Director
Volmerstrasse 5
12489 Berlin/Germany
Phone: +49 - 30 - 6392 - 7880
Fax: +49 - 30 - 6392 - 5501

Stay in touch and be the first to receive the latest news!